Boxer Capital Management, LLC

Boxer Capital sold 3,080,000 shares of TNGX at $3.14 on 2024-11-06; stock now down -78.0% from 52-week high, currently $2.83

Boxer Capital Management reduced its TNGX stake by -46.0%, selling 3,080,000 shares for $9,671,200.00 on 2024-11-06 at $3.14. The company is unprofitable with net income of $-29,167,000.00 against quarterly revenue of $11,607,000.00, though annual revenue growth reached +46.9%. Since the sale, the stock has fallen sharply: -58.9% over 30 days and -66.7% over 90 days, now trading at $2.83, which is -78.0% below the 52-week high of $12.88. Boxer also executed two additional sales at this ticker within the prior week (2024-10-25 and 2024-10-22), suggesting a deliberate reduction of exposure during a period of sustained deterioration. The magnitude of this liquidation—shedding nearly half the position—combined with steep price declines and the company's unprofitable operation, warrants investor scrutiny of what prompted the exit timing relative to publicly available fundamentals and near-term guidance.

Boxer Capital sold 633,000 TNGX shares at $6.87; stock now at $5.92, -54.0% from 52-week high; company unprofitable.

Boxer Capital Management, LLC sold 633,000 shares (633.0K shares) of Tango Therapeutics on 2024-10-25 at $6.87, reducing holdings from 7,323,642 to 6,690,642 shares (-8.6%). The sale occurred within a context of significant stock deterioration: the current price of $5.92 is -54.0% from the 52-week high of $12.88, and the stock has declined -20.8% over 30 days and -39.0% over 90 days. This represents the insider's third consecutive sale of TNGX in as many trading days (2024-10-21, 2024-10-22, 2024-10-25), suggesting a pattern of liquidation activity. Tango Therapeutics remains unprofitable with quarterly revenue of $19,875,000.00 but net income of $-25,551,000.00, though the company shows strong annual revenue growth of +46.9% year-over-year. The proximity of these three sales to peak valuations earlier in the year warrants examination of whether they represent a structured exit or response to operational concerns.

Boxer Capital Management sells 875,000 TNGX shares (10.7% of holdings) for $6.1M as stock declines 51.3% from 52-week high.

Boxer Capital Management executed 2 separate sales totaling 875,000 shares for $6,101,250.00 over two trading days (October 21-22, 2024) at a blended average price of $6.97, reducing its stake from 8,198,642 shares to 7,323,642 shares. The timing of this sale is notable against the stock's recent price action: the company trades at $6.27, which is -51.3% from its 52-week high of $12.88 and down 36.4% over the past 90 days. Tango Therapeutics remains unprofitable with a net income of $-25,551,000.00 against quarterly revenue of $19,875,000.00, though the company demonstrated annual revenue growth of +46.9%. The magnitude of the reduction (10.7% of pre-transaction holdings by a significant shareholder holding 7.32M shares post-sale) during a period of substantial stock depreciation warrants monitoring of the filer's conviction in the asset.